Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for pa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1443962/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832086528123207680 |
|---|---|
| author | Emad Dawoud Fathi Azribi Aref Chehal Shaheenah Dawood Syed Hammad Tirmazy Dina Hamza Hassan Jaafar Hussam Marashi |
| author_facet | Emad Dawoud Fathi Azribi Aref Chehal Shaheenah Dawood Syed Hammad Tirmazy Dina Hamza Hassan Jaafar Hussam Marashi |
| author_sort | Emad Dawoud |
| collection | DOAJ |
| description | Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of “HER2-low” expression as a targetable category has caused a paradigm shift in the management of breast cancer. Although initially developed to target HER2-positive breast cancer, trastuzumab deruxtecan (T-DXd), an ADC, has now also been approved to treat metastatic or unresectable HER2-low breast cancers. Despite the inherent specificity of an ADC, the risk of off-site toxicity exists and is an essential component while assessing the risk-benefit ratio of the treatment. Developing strategies to balance efficacy and safety is crucial, especially for newly approved therapies like T-DXd. Regional perspectives, cultural beliefs, and demographic factors influence treatment decisions and outcomes. The objective of this paper is to establish a UAE-specific consensus among oncologists on practical T-DXd treatment considerations and management of associated side effects. Establishing a consensus on monitoring and managing T-DXd side effects among experts can promote informed decision-making. |
| format | Article |
| id | doaj-art-ab4a9615439742309bedaae24a174c2d |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ab4a9615439742309bedaae24a174c2d2025-02-06T11:55:46ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14439621443962Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensusEmad Dawoud0Fathi Azribi1Aref Chehal2Shaheenah Dawood3Syed Hammad Tirmazy4Dina Hamza5Hassan Jaafar6Hussam Marashi7Department of Oncology, Tawam Hospital, Al Ain, United Arab EmiratesDepartment of Oncology, American Hospital, Dubai, United Arab EmiratesDepartment of Oncology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab EmiratesDepartment of Oncology, Mediclinic Middle East, Dubai, United Arab EmiratesDepartment of Oncology, Dubai Hospital, Dubai, United Arab EmiratesDepartment of Oncology, Dubai Hospital, Dubai, United Arab EmiratesDepartment of Oncology, Burjeel Hospital, Sharjah, United Arab EmiratesDepartment of Oncology, Tawam Hospital, Al Ain, United Arab EmiratesBreast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of “HER2-low” expression as a targetable category has caused a paradigm shift in the management of breast cancer. Although initially developed to target HER2-positive breast cancer, trastuzumab deruxtecan (T-DXd), an ADC, has now also been approved to treat metastatic or unresectable HER2-low breast cancers. Despite the inherent specificity of an ADC, the risk of off-site toxicity exists and is an essential component while assessing the risk-benefit ratio of the treatment. Developing strategies to balance efficacy and safety is crucial, especially for newly approved therapies like T-DXd. Regional perspectives, cultural beliefs, and demographic factors influence treatment decisions and outcomes. The objective of this paper is to establish a UAE-specific consensus among oncologists on practical T-DXd treatment considerations and management of associated side effects. Establishing a consensus on monitoring and managing T-DXd side effects among experts can promote informed decision-making.https://www.frontiersin.org/articles/10.3389/fonc.2024.1443962/fullHER2metastatic breast cancertrastuzumab deruxtecanT-DXdtargeted therapyantibody-drug conjugates |
| spellingShingle | Emad Dawoud Fathi Azribi Aref Chehal Shaheenah Dawood Syed Hammad Tirmazy Dina Hamza Hassan Jaafar Hussam Marashi Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus Frontiers in Oncology HER2 metastatic breast cancer trastuzumab deruxtecan T-DXd targeted therapy antibody-drug conjugates |
| title | Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus |
| title_full | Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus |
| title_fullStr | Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus |
| title_full_unstemmed | Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus |
| title_short | Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus |
| title_sort | monitoring and management of adverse effects associated with trastuzumab deruxtecan a uae specific consensus |
| topic | HER2 metastatic breast cancer trastuzumab deruxtecan T-DXd targeted therapy antibody-drug conjugates |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1443962/full |
| work_keys_str_mv | AT emaddawoud monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT fathiazribi monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT arefchehal monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT shaheenahdawood monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT syedhammadtirmazy monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT dinahamza monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT hassanjaafar monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus AT hussammarashi monitoringandmanagementofadverseeffectsassociatedwithtrastuzumabderuxtecanauaespecificconsensus |